Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

SLS vs CGEN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGEN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

CGEN Overall Winner 6-Pillar Tally: SLS 1 – 5 CGEN Matrix Metrics: SLS 2 – 8 CGEN

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over SELLAS Life Sciences Group, Inc. (SLS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SLS carries a Unified Composite Score of 34.1/100 (SELL) at $19.15 (N/M Forward P/E, 0.0% operating margin), whereas CGEN carries 49.8/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin).

  • Technical & Structure Timing Caution: SLS trades in a Neutral technical trend (BREAKOUT options phase, RSI 77.3); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SLS vs CGEN
SLS NASDAQ
SELLAS Life Sciences Group, Inc. Common Stock
Pharmaceutical Preparations
$19.15
+156.36% 1D
Market Cap $1.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.30β · 544% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 5.0 Fund 37.0 Flow 66.0 Mom 38.9
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 77
RSI-14: 77.3 · SMA20: $10.00 · SMA50: $11.02
CGEN NASDAQ Head-to-Head Winner
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
TTM Revenue $76M
Forward P/E 12.4x
Beta / 30D Vol 1.44β · 62% Vol
Unified Composite Score
49.8 / 100 HOLD
Tech 53.0 Fund 52.0 Flow 55.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $2.02 · SMA50: $2.18

6-Pillar Scorecard Institutional Category Breakdown (SLS 1 – 5 CGEN)

Columns: Metric · SLS · CGEN
1. Valuation Multiples CGEN
Forward P/E N/M 12.4x
Trailing P/E N/M 5.2x
PEG Ratio N/M 1.29x
EV / Revenue N/M 2.5x
2. Growth & Scale CGEN
Revenue Growth (YoY) -82.5% +102.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $76M
Market Cap $1.5B $193.2M
3. Profitability & Quality CGEN
Gross Margin N/A 86.2%
Operating Margin 0.0% 41.3%
Net Profit Margin 0.0% 47.9%
Return on Equity (ROE) -40.3% 57.2%
4. Balance Sheet & Cash Flow CGEN
Cash Generation (TTM) -$28M $32M EBITDA
Cash Flow Margin N/A 41.9% EBITDA Mgn
Net Cash / Leverage $138M Net Cash $4.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SLS
Options Structure Phase BREAKOUT BREAKDOWN
Current IV / %ile 250.1% (27th %ile) 89.7% (57th %ile)
Put/Call OI Skew 0.39x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CGEN
OpEx & R&D Intensity N/A 44.9% of Rev ($34M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SLS (2) vs CGEN (8)
Institutional Metric SLS CGEN Criterion Row Edge
Market Capitalization
Scale
$1.5B $193.2M Larger Scale SLS
Trailing P/E Ratio
Valuation
N/M 5.2x Lower Multiple CGEN
Forward P/E Ratio
Valuation
N/M 12.4x Lower Multiple CGEN
Revenue Growth (YoY)
Growth
-82.5% +102.1% Higher Growth CGEN
Operating Margin (TTM)
Profitability
0.0% 41.3% Higher Margin CGEN
Net Profit Margin
Profitability
0.0% 47.9% Higher Margin CGEN
Return on Equity (ROE)
Capital Efficiency
-40.3% 57.2% Higher ROE CGEN
52-Week Range Position
Momentum
76% ($1–$25) 33% ($1–$3) Stronger Trend SLS
Beta / 30D Volatility
Risk Regime
1.30β · 544% Vol 1.44β · 62% Vol Lower Realized Risk CGEN
Unified Institutional Score
Composite Signal
34.1 / 100 (SELL) 49.8 / 100 (HOLD) Higher Composite CGEN
Trailing 12M Revenue (USD)
Operating Scale
N/A $76M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 86.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.29x PEG · 2.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$28M ($138M Net Cash) $32M EBITDA ($4.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SLS +80.01 pp
SLS: +82.55% · CGEN: +2.54%
3M Horizon SLS +55.48 pp
SLS: +38.27% · CGEN: -17.21%
6M Horizon SLS +178.32 pp
SLS: +152.31% · CGEN: -26.01%
1Y Horizon SLS +1215.99 pp
SLS: +1239.16% · CGEN: +23.17%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SLS Revenue CGEN Revenue SLS Op. Margin CGEN Op. Margin Margin Leader
FY2016 N/A $0M N/A -4576.3% CGEN
FY2018 N/A $20M N/A -130.5% CGEN
FY2020 $0M $0M -893.8% -1574.8% SLS
FY2021 $10M $10M -332.8% -584.6% SLS
FY2022 $0M $10M -4195.0% -471.7% CGEN
FY2023 N/A $30M N/A -38.8% CGEN
FY2024 N/A $30M N/A -53.4% CGEN
FY2025 N/A $70M N/A 43.1% CGEN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SLS BREAKOUT
99d in phase · OBV ACCUMULATION
Current IV 250.1%
IV Percentile 27th %ile
Put/Call OI Skew 0.39x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact SLS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CGEN BREAKDOWN
143d in phase · OBV NEUTRAL
Current IV 89.7%
IV Percentile 57th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $19.15 · IV 151.5%

SLS Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($1,915)

Compare $1,915 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 151.5% ATM IV.

5-DAY BULLISH SWING Liq B

Nov 27 $20 / $23 Bull Call Spread

Buy 2x $20C · Sell 2x $23C · 10d

Net Entry $176 Debit
T+5d @ +5% Move +$26 (+15%)
Max Risk / Buffer $176 Capped
5d Edge & Liquidity 0.4x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $17 / $15 Bull Put Spread

Sell 4x $17P · Buy 4x $15P · 59d

Net Entry $340 Credit
Max Credit / Yield +$340 (+73.9% RoM)
Max Risk / Buffer -15.7% Cushion ($460 Mgn)
5d Edge & Liquidity 69% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SLS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CGEN Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $193.2M market capitalization and 41.3% operating margin.
OpEx & R&D Reinvestment 44.9% of Rev ($34M)
90D Engineering Disclosures 0 Published

Investor FAQ SLS vs CGEN Key Questions & Quantitative Answers

As of Nov 17, 2026, Compugen Ltd (CGEN) is the stronger overall head-to-head candidate over SELLAS Life Sciences Group, Inc. (SLS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SLS carries a Unified Composite Score of 34.1/100 (SELL) at $19.15 (N/M Forward P/E, 0.0% operating margin), whereas CGEN carries 49.8/100 (HOLD) at $2.02 (12.4x Forward P/E, 41.3% operating margin). Technical & Structure Timing Caution: SLS trades in a Neutral technical trend (BREAKOUT options phase, RSI 77.3); meanwhile CGEN is in a Breakdown options structure phase (RSI 46.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CGEN leads the Growth & Scale pillar: SLS posts -82.5% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CGEN at +102.1% YoY revenue growth and +0.0% YoY earnings growth on $76M TTM revenue (86.2% gross margin, 41.3% operating margin). Across the 8-period historical trajectory (FY2016 to FY2025), SLS cumulative revenue shifted N/A while CGEN shifted +250.0%. In operating R&D and SG&A reinvestment, SLS deploys N/A (0 90-day corporate R&D disclosures) versus 44.9% of Rev ($34M) (0 disclosures) for CGEN.

CGEN screens cheaper on headline valuation multiples. SLS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CGEN trades at 12.4x Forward P/E, 5.2x Trailing P/E, 1.29x PEG, and 2.5x EV/Revenue (41.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SLS (-40.3% ROE) versus CGEN (57.2% ROE) capital efficiency.

In options market volatility and institutional positioning, SLS carries 250.1% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 0.39x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.30β · 544% Vol realized risk). By comparison, CGEN carries 89.7% implied volatility (57th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.44β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.